These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 14745444)

  • 1. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
    Willett CG; Boucher Y; di Tomaso E; Duda DG; Munn LL; Tong RT; Chung DC; Sahani DV; Kalva SP; Kozin SV; Mino M; Cohen KS; Scadden DT; Hartford AC; Fischman AJ; Clark JW; Ryan DP; Zhu AX; Blaszkowsky LS; Chen HX; Shellito PC; Lauwers GY; Jain RK
    Nat Med; 2004 Feb; 10(2):145-7. PubMed ID: 14745444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
    Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
    Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular biology support for the use of bevacizumab in colorectal cancer.
    Doggrell SA
    Expert Opin Investig Drugs; 2004 Jun; 13(6):703-5. PubMed ID: 15174956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging.
    Koukourakis MI; Mavanis I; Kouklakis G; Pitiakoudis M; Minopoulos G; Manolas C; Simopoulos C
    Am J Clin Oncol; 2007 Jun; 30(3):315-8. PubMed ID: 17551312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology evaluation: bevacizumab, Genentech/Roche.
    Salgaller ML
    Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
    Xu L; Duda DG; di Tomaso E; Ancukiewicz M; Chung DC; Lauwers GY; Samuel R; Shellito P; Czito BG; Lin PC; Poleski M; Bentley R; Clark JW; Willett CG; Jain RK
    Cancer Res; 2009 Oct; 69(20):7905-10. PubMed ID: 19826039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
    Willett CG; Duda DG; di Tomaso E; Boucher Y; Czito BG; Vujaskovic Z; Vlahovic G; Bendell J; Cohen KS; Hurwitz HI; Bentley R; Lauwers GY; Poleski M; Wong TZ; Paulson E; Ludwig KA; Jain RK
    Nat Clin Pract Oncol; 2007 May; 4(5):316-21. PubMed ID: 17464339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts.
    Segerström L; Fuchs D; Bäckman U; Holmquist K; Christofferson R; Azarbayjani F
    Pediatr Res; 2006 Nov; 60(5):576-81. PubMed ID: 16988184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease.
    Coriat R; Mir O; Leblanc S; Ropert S; Brezault C; Chaussade S; Goldwasser F
    Inflamm Bowel Dis; 2011 Jul; 17(7):1632. PubMed ID: 21674721
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor inhibitors in colon cancer.
    Díaz-Rubio E
    Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion.
    Ribeiro SC; Vargas FS; Antonangelo L; Marchi E; Genofre EH; Acencio MM; Teixeira LR
    Respirology; 2009 Nov; 14(8):1188-93. PubMed ID: 19818055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
    Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
    Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of anti-VEGF antibody on retinal ganglion cells in rats.
    Iriyama A; Chen YN; Tamaki Y; Yanagi Y
    Br J Ophthalmol; 2007 Sep; 91(9):1230-3. PubMed ID: 17475701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.
    O'Connor JP; Carano RA; Clamp AR; Ross J; Ho CC; Jackson A; Parker GJ; Rose CJ; Peale FV; Friesenhahn M; Mitchell CL; Watson Y; Roberts C; Hope L; Cheung S; Reslan HB; Go MA; Pacheco GJ; Wu X; Cao TC; Ross S; Buonaccorsi GA; Davies K; Hasan J; Thornton P; del Puerto O; Ferrara N; van Bruggen N; Jayson GC
    Clin Cancer Res; 2009 Nov; 15(21):6674-82. PubMed ID: 19861458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma.
    Salnikov AV; Heldin NE; Stuhr LB; Wiig H; Gerber H; Reed RK; Rubin K
    Int J Cancer; 2006 Dec; 119(12):2795-802. PubMed ID: 17019708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
    Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
    J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
    Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
    J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic anti-VEGF antibodies.
    Lien S; Lowman HB
    Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.